We’re enabling scientists to perform world-class cancer research with the latest next generation sequencing platforms.
For more than ten years BGI has been partnering with some of the world’s leading research institutions and pharmaceutical companies wiht the goal of uncovering new insights into the biology of cancer that can lead to meaningful advances in personalized medicine.
Utilizing the industry’s latest next-generation sequencing (NGS) technologies, its global network and vast industry experience, BGI is uniquely positioned to deliver quick, accurate and cost effective answers in the eld of cancer genomics research including:
- Helping cancer researchers use whole genome, exome, and targeted amplicon next generation sequencing approaches to characterizecancer-associated mutations and other biomarkers.
- Enabling clinical trial researchers use next generation sequencing cancer panels to identify known cancer biomarkers within a patient population to accurately identify subsets of the population with increased sensitivity to the therapeutic being tested.
- Providing a wide range of xed cancer panels to enable rapid analysis of genes and mutation hotspots to and actionable variants in any type of cancer, including solid tumors